These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 34541884

  • 1. Circulating Tumor DNA Harboring the BRAFV600E Mutation May Predict Poor Outcomes of Primary Papillary Thyroid Cancer Patients.
    Sato A, Tanabe M, Tsuboi Y, Niwa T, Shinozaki-Ushiku A, Seto Y, Murakami Y.
    Thyroid; 2021 Dec; 31(12):1822-1828. PubMed ID: 34541884
    [Abstract] [Full Text] [Related]

  • 2. Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma.
    Condello V, Macerola E, Ugolini C, De Napoli L, Romei C, Materazzi G, Elisei R, Basolo F.
    Head Neck; 2018 Aug; 40(8):1752-1758. PubMed ID: 29566452
    [Abstract] [Full Text] [Related]

  • 3. Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAFV600E mutation in papillary thyroid carcinoma.
    Wang Z, Sun K, Jing C, Cao H, Ma R, Wu J.
    J Clin Lab Anal; 2019 Jul; 33(6):e22902. PubMed ID: 31021028
    [Abstract] [Full Text] [Related]

  • 4. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAFV600E mutation.
    Lee YK, Park KH, Park SH, Kim KJ, Shin DY, Nam KH, Chung WY, Lee EJ.
    Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
    [Abstract] [Full Text] [Related]

  • 5. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma.
    Ahn D, Park JS, Sohn JH, Kim JH, Park SK, Seo AN, Park JY.
    Auris Nasus Larynx; 2012 Apr; 39(2):198-203. PubMed ID: 21862261
    [Abstract] [Full Text] [Related]

  • 6. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates.
    Al-Salam S, Sharma C, Afandi B, Al Dahmani K, Al-Zahrani AS, Al Shamsi A, Al Kaabi J.
    PLoS One; 2020 Apr; 15(4):e0231341. PubMed ID: 32315324
    [Abstract] [Full Text] [Related]

  • 7. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
    Han PA, Kim HS, Cho S, Fazeli R, Najafian A, Khawaja H, McAlexander M, Dy B, Sorensen M, Aronova A, Sebo TJ, Giordano TJ, Fahey TJ, Thompson GB, Gauger PG, Somervell H, Bishop JA, Eshleman JR, Schneider EB, Witwer KW, Umbricht CB, Zeiger MA.
    Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
    [Abstract] [Full Text] [Related]

  • 8. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H, Youn YK.
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [Abstract] [Full Text] [Related]

  • 9. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH, Kim IJ, Lee BJ, Lee JC, Kim IS, Kim SJ, Kim WJ, Jeon YK, Kim SS, Kim YK.
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [Abstract] [Full Text] [Related]

  • 10. BRAFV600E mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features.
    Shi C, Cao J, Shi T, Liang M, Ding C, Lv Y, Zhang W, Li C, Gao W, Wu G, Man J.
    World J Surg Oncol; 2020 Jun 27; 18(1):145. PubMed ID: 32593310
    [Abstract] [Full Text] [Related]

  • 11. BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.
    Lai HF, Hang JF, Kuo PC, Kuo CS, Yao SF, Chen JY, Lee CH.
    Ann Surg Oncol; 2024 May 27; 31(5):3495-3501. PubMed ID: 38300401
    [Abstract] [Full Text] [Related]

  • 12. Detection of BRAF V600E mutation in fine-needle aspiration fluid of papillary thyroid carcinoma by droplet digital PCR.
    Xu X, Ma X, Zhang X, Cao G, Tang Y, Deng X, Kang Z, Li M, Guan M.
    Clin Chim Acta; 2019 Apr 27; 491():91-96. PubMed ID: 30682328
    [Abstract] [Full Text] [Related]

  • 13. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK, Chong A, Ha JM, Jung CK, O JH, Kim SH.
    Clin Endocrinol (Oxf); 2017 Jul 27; 87(1):73-79. PubMed ID: 28329426
    [Abstract] [Full Text] [Related]

  • 14. Correlation between US-FNAC with BRAF V600E Mutation Analysis and Central Neck Lymph Node Metastasis in cN0 Papillary Thyroid Cancer.
    Li R, Hao J, Zhu Z, Qiao X, Wang L, Zhou Z.
    Biomed Res Int; 2021 Jul 27; 2021():9937742. PubMed ID: 34307677
    [Abstract] [Full Text] [Related]

  • 15. Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma.
    Wei X, Wang X, Xiong J, Li C, Liao Y, Zhu Y, Mao J.
    Biomed Res Int; 2022 Jul 27; 2022():9959649. PubMed ID: 35647194
    [Abstract] [Full Text] [Related]

  • 16. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
    Krishnamurthy A, Ramshankar V, Murherkar K, Vidyarani S, Raghunandhan GC, Das A, Desai PB, Albert K.
    Indian J Cancer; 2017 Jul 27; 54(1):372-378. PubMed ID: 29199726
    [Abstract] [Full Text] [Related]

  • 17. Increased diagnostic sensitivity of palpation-guided thyroid nodule fine-needle aspiration cytology by BRAF V600E-mutation analysis.
    Gimm O, Ivansson K, Beka E, Rossitti HM, Garvin S, Söderkvist P.
    J Pathol Clin Res; 2021 Nov 27; 7(6):556-564. PubMed ID: 34156770
    [Abstract] [Full Text] [Related]

  • 18. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M, Yan C, Xiao J, Wang T, Ling R.
    Diagn Pathol; 2019 Jul 12; 14(1):74. PubMed ID: 31300059
    [Abstract] [Full Text] [Related]

  • 19. Predictive Value of BRAFV600E Mutation for Lymph Node Metastasis in Papillary Thyroid Cancer: A Meta-analysis.
    Song JY, Sun SR, Dong F, Huang T, Wu B, Zhou J.
    Curr Med Sci; 2018 Oct 12; 38(5):785-797. PubMed ID: 30341513
    [Abstract] [Full Text] [Related]

  • 20. The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome.
    Russo M, Malandrino P, Nicolosi ML, Manusia M, Marturano I, Trovato MA, Pellegriti G, Frasca F, Vigneri R.
    Thyroid; 2014 Aug 12; 24(8):1267-74. PubMed ID: 24787545
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.